Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Abstract Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse. Esketamine nasal spray, an N-methyl-D-aspartate receptor antagonist, is a novel,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-12-01
|
| Series: | Middle East Current Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43045-023-00369-3 |
| _version_ | 1797398244951588864 |
|---|---|
| author | Nahida Nayaz Ahmed Faisal Albishi Suhail A. Khan Ammar Alsayegh Emmanuel Stip Samer Makhoul |
| author_facet | Nahida Nayaz Ahmed Faisal Albishi Suhail A. Khan Ammar Alsayegh Emmanuel Stip Samer Makhoul |
| author_sort | Nahida Nayaz Ahmed |
| collection | DOAJ |
| description | Abstract Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse. Esketamine nasal spray, an N-methyl-D-aspartate receptor antagonist, is a novel, fast-acting treatment option for TRD. This article addresses common questions in Gulf Cooperation Council (GCC) countries regarding esketamine nasal spray by discussing the latest clinical evidence and by providing expert opinions. Methods Six expert psychiatrists from the GCC region with clinical experience in TRD reviewed and critically appraised published evidence on esketamine nasal spray for TRD and considered clinical guidelines, expert opinions and consensus statements. Consensus views were reached on clinical questions pertinent to implementing esketamine nasal spray for TRD in the GCC region. Results Clinical questions on patient identification, selection of serotonin reuptake inhibitors/serotonin and norepinephrine reuptake inhibitors, treatment duration, management of adverse events and clinical requirements for the safe administration of esketamine nasal spray were addressed. Conclusions Esketamine nasal spray represents a new treatment paradigm for TRD. This article provides clinical guidance based on the latest evidence and clinical experience to help mental health practitioners implement esketamine nasal spray into everyday clinical practice. |
| first_indexed | 2024-03-09T01:21:49Z |
| format | Article |
| id | doaj.art-cb91359e43814e20bbe6609ea5234a61 |
| institution | Directory Open Access Journal |
| issn | 2090-5416 |
| language | English |
| last_indexed | 2024-03-09T01:21:49Z |
| publishDate | 2023-12-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Middle East Current Psychiatry |
| spelling | doaj.art-cb91359e43814e20bbe6609ea5234a612023-12-10T12:05:43ZengSpringerOpenMiddle East Current Psychiatry2090-54162023-12-0130111510.1186/s43045-023-00369-3Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countriesNahida Nayaz Ahmed0Faisal Albishi1Suhail A. Khan2Ammar Alsayegh3Emmanuel Stip4Samer Makhoul5Abu Dhabi Health Services Company – SEHAAddiction Treatment Unit, Ministry of HealthEradah and Mental Health Complex, Mental Health ServicesKuwait Center for Mental HealthUnited Arab Emirates UniversityEmirates Future Neuroscience CenterAbstract Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse. Esketamine nasal spray, an N-methyl-D-aspartate receptor antagonist, is a novel, fast-acting treatment option for TRD. This article addresses common questions in Gulf Cooperation Council (GCC) countries regarding esketamine nasal spray by discussing the latest clinical evidence and by providing expert opinions. Methods Six expert psychiatrists from the GCC region with clinical experience in TRD reviewed and critically appraised published evidence on esketamine nasal spray for TRD and considered clinical guidelines, expert opinions and consensus statements. Consensus views were reached on clinical questions pertinent to implementing esketamine nasal spray for TRD in the GCC region. Results Clinical questions on patient identification, selection of serotonin reuptake inhibitors/serotonin and norepinephrine reuptake inhibitors, treatment duration, management of adverse events and clinical requirements for the safe administration of esketamine nasal spray were addressed. Conclusions Esketamine nasal spray represents a new treatment paradigm for TRD. This article provides clinical guidance based on the latest evidence and clinical experience to help mental health practitioners implement esketamine nasal spray into everyday clinical practice.https://doi.org/10.1186/s43045-023-00369-3Esketamine nasal sprayTreatment-resistant depressionMajor depressive disorderGulf Cooperation Council |
| spellingShingle | Nahida Nayaz Ahmed Faisal Albishi Suhail A. Khan Ammar Alsayegh Emmanuel Stip Samer Makhoul Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries Middle East Current Psychiatry Esketamine nasal spray Treatment-resistant depression Major depressive disorder Gulf Cooperation Council |
| title | Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries |
| title_full | Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries |
| title_fullStr | Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries |
| title_full_unstemmed | Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries |
| title_short | Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries |
| title_sort | management of treatment resistant depression with esketamine nasal spray clinical questions for daily practice in gulf cooperation council countries |
| topic | Esketamine nasal spray Treatment-resistant depression Major depressive disorder Gulf Cooperation Council |
| url | https://doi.org/10.1186/s43045-023-00369-3 |
| work_keys_str_mv | AT nahidanayazahmed managementoftreatmentresistantdepressionwithesketaminenasalsprayclinicalquestionsfordailypracticeingulfcooperationcouncilcountries AT faisalalbishi managementoftreatmentresistantdepressionwithesketaminenasalsprayclinicalquestionsfordailypracticeingulfcooperationcouncilcountries AT suhailakhan managementoftreatmentresistantdepressionwithesketaminenasalsprayclinicalquestionsfordailypracticeingulfcooperationcouncilcountries AT ammaralsayegh managementoftreatmentresistantdepressionwithesketaminenasalsprayclinicalquestionsfordailypracticeingulfcooperationcouncilcountries AT emmanuelstip managementoftreatmentresistantdepressionwithesketaminenasalsprayclinicalquestionsfordailypracticeingulfcooperationcouncilcountries AT samermakhoul managementoftreatmentresistantdepressionwithesketaminenasalsprayclinicalquestionsfordailypracticeingulfcooperationcouncilcountries |